Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


1 Infect Immun
1 J Infect
3 J Infect Dis
3 J Virol
2 Lancet
2 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
1 PLoS Comput Biol
2 PLoS One
22 Vaccine
1 Virology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


    RSV vaccines administered in error to infants and pregnant people, CDC reports.
    BMJ. 2024;384:q236.

    Measles outbreaks: Investing in patient relationships through GP continuity will be key to boosting MMR confidence.
    BMJ. 2024;384:q221.

    Infect Immun

  3. BARNES KB, Brett P, Burtnick M, Vente A, et al
    Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in Balb/c mice.
    Infect Immun. 2024 Jan 30:e0045523. doi: 10.1128/iai.00455.
    PubMed         Abstract available

    J Infect

  4. HARRISON T, Clark J, Darton TC
    Less is more: uptake of recommended vaccines in a UK Travel Clinic.
    J Infect. 2024 Jan 25:S0163-4453(24)00027-6. doi: 10.1016/j.jinf.2024.

    J Infect Dis

  5. SHAW CA, Mithani R, Kapoor A, Dhar R, et al
    Safety, Tolerability and Immunogenicity of a mRNA-based RSV Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
    J Infect Dis. 2024 Jan 31:jiae035. doi: 10.1093.
    PubMed         Abstract available

  6. MCCARTHY KN, Hone S, McLoughlin RM, Mills KHG, et al
    IL-17 and IFN-gamma-producing respiratory tissue resident memory CD4 T cells persist for decades in adults immunized as children with whole cell pertussis vaccines.
    J Infect Dis. 2024 Jan 30:jiae034. doi: 10.1093.
    PubMed         Abstract available

  7. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
    Hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural infection or vaccination alone.
    J Infect Dis. 2024 Jan 29:jiae046. doi: 10.1093.

    J Virol

  8. BRICKER TL, Joshi A, Soudani N, Scheaffer SM, et al
    Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    J Virol. 2024 Feb 2:e0120623. doi: 10.1128/jvi.01206.
    PubMed         Abstract available

  9. ANDERSON EM, Coller B-AG
    Translational success of fundamental virology: a VSV-vectored Ebola vaccine.
    J Virol. 2024 Feb 2:e0162723. doi: 10.1128/jvi.01627.
    PubMed         Abstract available

  10. MU S, Chen L, Dong H, Li S, et al
    Enhanced antigen-specific CD8 T cells contribute to early protection against FMDV through swine DC vaccination.
    J Virol. 2024 Jan 30:e0200223. doi: 10.1128/jvi.02002.
    PubMed         Abstract available


  11. HARRIS E
    Missed Vaccine Doses Tied to Worse COVID-19 Outcomes.
    JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28340.


  12. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    PubMed         Abstract available

  13. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.

    MMWR Morb Mortal Wkly Rep

  14. LINK-GELLES R, Ciesla AA, Mak J, Miller JD, et al
    Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Pro
    MMWR Morb Mortal Wkly Rep. 2024;73:77-83.
    PubMed         Abstract available

  15. MONACH PA, Anand ST, Fillmore NR, La J, et al
    Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:57-61.
    PubMed         Abstract available

    N Engl J Med

    Three Dengue Vaccines - What Now?
    N Engl J Med. 2024;390:464-465.

  17. KALLAS EG, Cintra MAT, Moreira JA, Patino EG, et al
    Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
    N Engl J Med. 2024;390:397-408.
    PubMed         Abstract available

    PLoS Comput Biol

  18. CHAN LYH, Ro G, Midtbo JE, Di Ruscio F, et al
    Modeling geographic vaccination strategies for COVID-19 in Norway.
    PLoS Comput Biol. 2024;20:e1011426.
    PubMed         Abstract available

    PLoS One

  19. GEHRING S, Kowalzik F, Okasha O, Engelmann T, et al
    A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines.
    PLoS One. 2024;19:e0294025.
    PubMed         Abstract available

  20. LIU CC, Ling J, Zahry NR, Liu C, et al
    Using the Theory of Planned Behavior to determine COVID-19 vaccination intentions and behavior among international and domestic college students in the United States.
    PLoS One. 2024;19:e0293130.
    PubMed         Abstract available


  21. SUMNER T, Clark RA, Mukandavire C, Portnoy A, et al
    Modelling the health and economic impacts ofM72/AS01(E) vaccination and BCG-revaccination: Estimates for South Africa.
    Vaccine. 2024 Feb 1:S0264-410X(24)00096-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  22. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  23. DE DEUS N, Chissaque A, Bauhofer A, Barata A, et al
    Safety of incidental exposure to the novel oral poliovirus vaccine type 2 in pregnancy: A longitudinal observational study in Mozambique, 2022-2023.
    Vaccine. 2024 Feb 1:S0264-410X(24)00095-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  24. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  25. LEVIN A, Yeung KHT, Hutubessy R
    Systematic review of cost projections of new vaccine introduction.
    Vaccine. 2024 Jan 25:S0264-410X(24)00024-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  26. HALL E, Mahon BE, Peacock G
    The U.S. COVID-19 vaccination program: A look back and future directions.
    Vaccine. 2024 Jan 26:S0264-410X(24)00065-3. doi: 10.1016/j.vaccine.2024.

  27. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  28. MURATA F, Maeda M, Ono R, Fukuda H, et al
    Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
    Vaccine. 2024 Jan 27:S0264-410X(24)00072-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  29. VIDLUND J, Gelalcha BD, Gillespie BE, Agga GE, et al
    Efficacy of novel staphylococcal surface associated protein vaccines against Staphylococcus aureus and non-aureus staphylococcal mastitis in dairy cows.
    Vaccine. 2024 Jan 27:S0264-410X(24)00079-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  30. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  31. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  32. XIAOFEI L, Yudan LI, Qinghui C, Jiaming S, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
    Vaccine. 2024 Jan 30:S0264-410X(24)00080-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  33. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  34. BURNS KE, Dube E, Nascimento HG, Meyer SB, et al
    Erratum to "Examining vaccine hesitancy among a diverse sample of Canadian adults" [Vaccine 42(2) (2024) 129-135].
    Vaccine. 2024 Jan 30:S0264-410X(24)00061-6. doi: 10.1016/j.vaccine.2024.

  35. POLAND GA, Black S
    Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.
    Vaccine. 2024 Jan 30:S0264-410X(24)00070-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  36. KOFF WC, Anandkumar A, Poland GA
    AI and the future of vaccine development.
    Vaccine. 2024 Jan 30:S0264-410X(24)00071-9. doi: 10.1016/j.vaccine.2024.

  37. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  38. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  39. SLAVKOVSKY R, Callen E, Pecenka C, Mvundura M, et al
    Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Vaccine. 2024 Jan 31:S0264-410X(24)00118-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  40. SCHONBORN L, Pavord S, Chen VMY, Pai M, et al
    Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Jan 31:S0264-410X(24)00057-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  41. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  42. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available


  43. HUONG TN, Lee ZQ, Lai SK, Lee HY, et al
    Evidence that an interaction between the respiratory syncytial virus F and G proteins at the distal ends of virus filaments mediates efficient multiple cycle infection.
    Virology. 2024;591:109985.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.